UBS: Maintains "Buy" rating on HUTCHMED (00013.HK) with a target price of HK$29.5
Zhitong Finance APP has learned that UBS released a research report stating that Sovleplenib (a Syk inhibitor) has been approved in China via priority review for the treatment of ITP and wAIHA, which the bank considers positive and better than expected. The bank maintains its "Buy" rating on HUTCHMED (00013.HK) and a target price of HK$29.5.
Latest

